Exhibit 107

 

Calculation of Filing Fee Table

 

Form F-3

(Form Type)

 

Can-Fite BioPharma Ltd.

(Exact name of registrant as specified in its charter)

 

Table 1 – Newly Registered Securities

 

   Security
Type		  Security Class
Title (1)		  Fee
Calculation
or Carry
Forward
Rule		  Amount
Registered (2)		   Proposed
Maximum
Offering
Price Per
Unit (3)		   Maximum
Aggregate
Offering
Price(3)		   Fee Rate   Amount of
Registration
Fee		 
Fees to Be Paid  Equity  Ordinary shares, no par value, underlying Warrants to Purchase American Depositary Shares (4)  Rule 457(c)   1,774,285,800   $2.33   $13,780,286.38    0.0001476   $2,033.97 
Fees Previously Paid                                  
  Total Offering Amounts               $13,780,286.38        $2,033.97 
  Total Fees Previously Paid                         — 
   Total Fee Offsets                          — 
   Net Fee Due                         $2,033.97 

 

(1) American Depositary Shares, or ADSs, issuable upon deposit of the ordinary shares registered hereby have been registered pursuant to a separate registration statement on Form F-6 (File No. 333-183741). Each American Depositary Share represents three hundred (300) ordinary shares.

 

(2) This registration statement also includes an indeterminate number of shares underlying the ADSs that may become offered, issuable or sold to prevent dilution resulting from stock splits, stock dividends and similar transactions, which are included pursuant to Rule 416 under the Securities Act of 1933, as amended.

 

(3) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) promulgated under the Securities Act of 1933, as amended, based on the average of the equivalent high and low sales prices of the ADSs on the NYSE American on August 27, 2024, divided by 300 (to give effect to the 1:300 ratio of ADSs to ordinary shares).

 

(4) Consists of (i) 1,714,285,800 ordinary shares issuable upon the exercise of new warrants issued to a certain holder in connection with the warrant repricing and (ii) 60,000,000  ordinary shares issuable upon the exercise of new warrants issued to the placement agent in connection with the warrant repricing.